Roivant Sciences Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roivant Sciences Ltd.
The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.
Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.
The company lowered Paxlovid and Comirnaty 2023 revenue projections by $9bn, announced plans for the commercial transition of the products, and revealed a cost-cutting plan.
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.